1887

Abstract

Formaldehyde-inactivated virus samples from type 1 poliovirus live-attenuated strains were prepared in the laboratory. The effect of treatment with formaldehyde on virus infectivity and immunogenicity in mice was investigated and the results compared with those from Mahoney wild-type poliovirus strain, the common type 1 component in commercial inactivated polio vaccines (IPV). Differences in the potency and specificity between these experimental vaccines were identified in both normal mice and transgenic mice expressing the human poliovirus receptor. The possible advantages/disadvantages of using live-attenuated strains for IPV production are discussed in the context of the global polio eradication initiative. A novel transgenic mouse model to study the immune protection induced by IPV preparations is described.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19088-0
2003-07-01
2020-01-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/7/vir841781.html?itemId=/content/journal/jgv/10.1099/vir.0.19088-0&mimeType=html&fmt=ahah

References

  1. Anon. ( 2001; ). Acute flaccid paralysis associated with circulating vaccine-derived poliovirus – Philippines, 2001. Morb Mortal Wkly Rep 50, 874–875.
    [Google Scholar]
  2. Cabasso, V. J., Jervis, G. A., Moyer, A. W., Roca-Garcia, M., Orsi, E. V. & Cox, H. R. ( 1959; ). Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. In Live Poliovirus Vaccines. First International Conference on Live Poliovirus Vaccines, pp. 102–134. Washington, DC: Pan American Sanitary Bureau.
  3. Centers for Disease Control & Prevention ( 2001; ). Circulation of a type 2 vaccine-derived poliovirus – Egypt, 1982–1993. JAMA 285, 1148–1149.
    [Google Scholar]
  4. Doi, Y., Abe, S., Yamamoto, H. & 8 other authors ( 2001; ). Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol 105, 163–169.
    [Google Scholar]
  5. Dowdle, W. R., Featherstone, D. A., Birmingham, M. E., Hull, H. F. & Aylward, R. B. ( 1999; ). Poliomyelitis eradication. Virus Res 62, 185–192.[CrossRef]
    [Google Scholar]
  6. Dowdle, W. R., Gary, H. E., Sanders, R. & van Loon, A. M. ( 2002; ). Can post-eradication laboratory containment of wild polioviruses be achieved? Bull World Health Organ 80, 311–316.
    [Google Scholar]
  7. Ferguson, M., Wood, D. J. & Minor, P. D. ( 1993; ). Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74, 685–690.[CrossRef]
    [Google Scholar]
  8. Hovi, T. ( 2001; ). Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 19, 2268–2272.[CrossRef]
    [Google Scholar]
  9. Kersten, G., Hazendonk, T. & Beuvery, C. ( 1999; ). Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17, 2059–2066.[CrossRef]
    [Google Scholar]
  10. Kew, O., Morris-Glasgow, V., Landaverde, M. & 21 other authors ( 2002; ). Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 14, 14.
    [Google Scholar]
  11. Koprowski, H. ( 1958; ). Vaccination with modified active viruses. In Poliomyelitis. Papers and Discussion Presented at the Fourth International Poliomyelitis Conference, pp. 112–123. Philadelphia: Lippincott.
  12. Lu, H. H., Yang, C. F., Murdin, A. D., Klein, M. H., Harber, J. J., Kew, O. M. & Wimmer, E. ( 1994; ). Mouse neurovirulence determinants of poliovirus type 1 strain LS – a map to the coding regions of capsid protein VP1 and proteinase 2Apro. J Virol 68, 7507–7515.
    [Google Scholar]
  13. Martin, J. & Minor, P. D. ( 2002; ). Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 76, 5339–5349.[CrossRef]
    [Google Scholar]
  14. McGoldrick, A., Macadam, A. J., Dunn, G., Rowe, A., Burlison, J., Minor, P. D., Meredith, J., Evans, D. J. & Almond, J. W. ( 1995; ). Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 69, 7601–7605.
    [Google Scholar]
  15. Melnick, J. L. ( 1994; ). Live attenuated poliovirus vaccines. In Vaccines, pp. 155–204. Edited by S. A. Plotkin & E. A. Mortimer, Jr. Philadelphia: W. B. Saunders.
  16. Minor, P. D. ( 1980; ). Comparative biochemical studies of type 3 poliovirus. J Virol 34, 73–84.
    [Google Scholar]
  17. Minor, P. D. ( 1990; ). Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 161, 121–154.
    [Google Scholar]
  18. Minor, P. D., John, A., Ferguson, M. & Icenogle, J. P. ( 1986; ). Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 67, 693–706.[CrossRef]
    [Google Scholar]
  19. Murdin, A. D., Barreto, L. & Plotkin, S. ( 1996; ). Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735–746.[CrossRef]
    [Google Scholar]
  20. Murph, J. R., Grose, C., McAndrew, P., Mickiewicz, C., Mento, S., Cano, F., Radick, L., Ritchey, M. & Stout, M. G. ( 1988; ). Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 7, 760–765.[CrossRef]
    [Google Scholar]
  21. Salk, J., Drucker, J. A. & Malvy, D. ( 1994; ). Noninfectious poliovirus vaccine. In Vaccines, pp. 205–228. Edited by S. A. Plotkin & E. A. Mortimer, Jr. Philadelphia: W. B. Saunders.
  22. Singer, C., Knauert, F., Bushar, G., Klutch, M., Lundquist, R. & Quinnan, G. V., Jr ( 1989; ). Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand 17, 137–150.[CrossRef]
    [Google Scholar]
  23. Strebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A. & Hinman, A. R. ( 1992; ). Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14, 568–579.[CrossRef]
    [Google Scholar]
  24. Taffs, R. E., Chernokhvostova, Y. V., Dragunsky, E. M., Nomura, T., Hioki, K., Beuvery, E. C., Fitzgerald, E. A., Levenbook, I. S. & Asher, D. M. ( 1997; ). Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. J Infect Dis 175, 441–444.[CrossRef]
    [Google Scholar]
  25. Toyoda, H., Kohara, M., Kataoka, Y., Suganuma, T., Omata, T., Imura, N. & Nomoto, A. ( 1984; ). Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J Mol Biol 174, 561–585.[CrossRef]
    [Google Scholar]
  26. Twomey, T., Newman, J., Burrage, T., Piatti, P., Lubroth, J. & Brown, F. ( 1995; ). Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13, 1603–1610.[CrossRef]
    [Google Scholar]
  27. World Health Organization ( 1997; ). Manual for the Virological Investigation of Poliomyelitis. Geneva: World Health Organization.
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19088-0
Loading
/content/journal/jgv/10.1099/vir.0.19088-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error